(Q34327773)

1 August 2017

1 reference

title

The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia (English)

1 reference

1 August 2017

0 references

Joseph T Coyle

1

1 reference

PubMed ID

15205876

1 August 2017

Guochuan Tsai

series ordinal

2

1 reference

1 August 2017

25 November 2003

1 reference

1 August 2017

1 reference

1 August 2017

174

1 reference

1 August 2017

1

1 reference

1 August 2017

32-38

1 reference

https://scigraph.springernature.com/pub.10.1007/s00213-003-1709-2

1 August 2017

0 references

cites work

N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells

1 reference

12 December 2020

D-serine added to clozapine for the treatment of schizophrenia

1 reference

12 December 2020

Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo

1 reference

12 December 2020

Increased cortical kynurenate content in schizophrenia

1 reference

12 December 2020

Effect of Phencyclidine in Chronic Schizophrenics

1 reference

12 December 2020

Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients

1 reference

12 December 2020

Cloning of the human glycine transporter type 1: molecular and pharmacological characterization of novel isoform variants and chromosomal localization of the gene in the human and mouse genomes

1 reference

12 December 2020

Linking Hebb's coincidence-detection to memory formation

1 reference

12 December 2020

Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population

1 reference

12 December 2020

Excitotoxicity, apoptosis and neuropsychiatric disorders

1 reference

12 December 2020

Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics.

1 reference

12 December 2020

Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis.

1 reference

12 December 2020

Modulation of N-methyl-D-aspartate receptor function by glycine transport

1 reference

12 December 2020

D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor

1 reference

12 December 2020

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia

1 reference

12 December 2020

Subchronic treatment with either clozapine, olanzapine or haloperidol produces a hyposensitive response of the rat cortical cells to N-methyl-D-aspartate.

1 reference

12 December 2020

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

1 reference

12 December 2020

A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia

1 reference

12 December 2020

Generation and characterisation of stable cell lines expressing recombinant human N-methyl-D-aspartate receptor subtypes

1 reference

12 December 2020

Comparative analysis of glutamate transporter expression in rat brain using differential double in situ hybridization.

1 reference

12 December 2020

D-serine nephrotoxicity. The nature of proteinuria, glucosuria, and aminoaciduria in acute tubular necrosis

1 reference

12 December 2020

Amelioration of negative symptoms in schizophrenia by glycine.

1 reference

12 December 2020

beta-NAAG rescues LTP from blockade by NAAG in rat dentate gyrus via the type 3 metabotropic glutamate receptor

1 reference

12 December 2020

Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses.

1 reference

12 December 2020

Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia

1 reference

12 December 2020

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

1 reference

12 December 2020

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia

1 reference

12 December 2020

NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine.

1 reference

12 December 2020

Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine

1 reference

12 December 2020

Recent advances in the phencyclidine model of schizophrenia

1 reference

12 December 2020

Defining the course of brain structural change and plasticity in schizophrenia

1 reference

12 December 2020

Glutamate carboxypeptidase II is expressed by astrocytes in the adult rat nervous system

1 reference

12 December 2020

Placebo-controlled trial of glycine added to clozapine in schizophrenia

1 reference

12 December 2020

Direct calcium binding results in activation of brain serine racemase

1 reference

12 December 2020

Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG).

1 reference

12 December 2020

Study of a new schizophrenomimetic drug; sernyl.

1 reference

12 December 2020

Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.

1 reference

12 December 2020

Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers

1 reference

12 December 2020

Neuregulin 1 and susceptibility to schizophrenia

1 reference

12 December 2020

D-serine added to antipsychotics for the treatment of schizophrenia

1 reference

12 December 2020

Neuregulin and ErbB receptor signaling pathways in the nervous system

1 reference

12 December 2020

Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia.

1 reference

12 December 2020

The glycine transporter type 1 inhibitor N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior.

1 reference

12 December 2020

D-cycloserine added to clozapine for patients with schizophrenia

1 reference

12 December 2020

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.

1 reference

12 December 2020

Abnormal excitatory neurotransmitter metabolism in schizophrenic brains

1 reference

12 December 2020

Ionotropic glutamate receptors as therapeutic targets in schizophrenia

1 reference

12 December 2020

A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors.

1 reference

12 December 2020

Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia

1 reference

12 December 2020

Effects of ketamine on leading saccades during smooth-pursuit eye movements may implicate cerebellar dysfunction in schizophrenia

1 reference

12 December 2020

Pharmacological assessment of the role of the glycine transporter GlyT-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes

1 reference

12 December 2020

The emerging role of glutamate in the pathophysiology and treatment of schizophrenia

1 reference

12 December 2020

Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia

1 reference

12 December 2020

d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study

1 reference

12 December 2020

Treatment-resistant schizophrenia--the role of clozapine

1 reference

12 December 2020

Interaction of [3H]MK-801 with multiple states of the N-methyl-D-aspartate receptor complex of rat brain

1 reference

12 December 2020

Dopamine receptors, neuroleptics, and schizophrenia

1 reference

12 December 2020

10.1007/S00213-003-1709-2

Identifiers

DOI

1 reference

PubMed ID

15205876

Dimensions Publication ID

1 August 2017

0 references

1 reference

PubMed ID

15205876